Abstract | OBJECTIVE:
Calcitriol analogues might represent an interesting new therapy for benign prostate hyperplasia (BPH). We here report the preclinical characterization of BXL-628, an analogue selected for an ongoing double-blind, randomized, placebo-controlled phase II trial in BPH. DESIGN: Experiments with BXL-628 were carried out in human BPH cells and in the ventral prostate of intact and castrated rats. METHODS: BPH cell and rat prostate growth were evaluated along with morphological and biochemical hallmarks of apoptosis. RESULTS: CONCLUSIONS:
BXL-628 inhibited in vitro and in vivo prostate cell proliferation, and therefore might represent a novel, interesting option for the treatment of BPH.
|
Authors | C Crescioli, P Ferruzzi, A Caporali, M Scaltriti, S Bettuzzi, R Mancina, S Gelmini, M Serio, D Villari, G B Vannelli, E Colli, L Adorini, M Maggi |
Journal | European journal of endocrinology
(Eur J Endocrinol)
Vol. 150
Issue 4
Pg. 591-603
(Apr 2004)
ISSN: 0804-4643 [Print] England |
PMID | 15080791
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
|
Topics |
- Animals
- Calcitriol
(administration & dosage, analogs & derivatives)
- Cell Division
(drug effects)
- Clinical Trials, Phase II as Topic
- Drug Evaluation, Preclinical
- Humans
- Male
- Orchiectomy
- Prostate
(drug effects, pathology)
- Prostatic Hyperplasia
(drug therapy, pathology)
- Randomized Controlled Trials as Topic
- Rats
- Rats, Sprague-Dawley
- Tumor Cells, Cultured
(drug effects)
|